A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Pfizer Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 14,801 shares of PFE stock, worth $395,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,801
Previous 8,842 67.39%
Holding current value
$395,778
Previous $247,000 73.28%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$27.7 - $31.39 $165,064 - $187,053
5,959 Added 67.39%
14,801 $428,000
Q2 2024

Aug 09, 2024

SELL
$25.26 - $29.6 $8.79 Million - $10.3 Million
-347,911 Reduced 97.52%
8,842 $247,000
Q1 2024

May 09, 2024

SELL
$25.89 - $29.73 $3.13 Million - $3.59 Million
-120,868 Reduced 25.31%
356,753 $9.9 Million
Q4 2023

Feb 09, 2024

SELL
$26.13 - $33.94 $40.9 Million - $53.1 Million
-1,564,632 Reduced 76.61%
477,621 $13.8 Million
Q3 2023

Nov 13, 2023

BUY
$32.09 - $37.51 $8.7 Million - $10.2 Million
271,052 Added 15.3%
2,042,253 $67.7 Million
Q2 2023

Aug 10, 2023

BUY
$36.12 - $41.79 $3.01 Million - $3.49 Million
83,419 Added 4.94%
1,771,201 $65 Million
Q1 2023

May 09, 2023

BUY
$39.39 - $51.28 $15.4 Million - $20 Million
390,628 Added 30.11%
1,687,782 $68.9 Million
Q4 2022

Feb 10, 2023

BUY
$41.75 - $54.5 $54.2 Million - $70.7 Million
1,297,154 New
1,297,154 $66.5 Million
Q2 2022

Aug 05, 2022

SELL
$46.53 - $55.17 $1.36 Million - $1.61 Million
-29,125 Reduced 20.33%
114,139 $5.98 Million
Q1 2022

May 12, 2022

SELL
$45.75 - $56.69 $25.3 Million - $31.3 Million
-552,661 Reduced 79.41%
143,264 $7.42 Million
Q4 2021

Feb 10, 2022

SELL
$41.32 - $61.25 $67 Million - $99.4 Million
-1,622,491 Reduced 69.98%
695,925 $41.1 Million
Q3 2021

Nov 12, 2021

BUY
$39.25 - $50.42 $25.8 Million - $33.1 Million
656,422 Added 39.5%
2,318,416 $99.7 Million
Q2 2021

Aug 12, 2021

BUY
$35.91 - $40.68 $18.6 Million - $21.1 Million
519,351 Added 45.45%
1,661,994 $65.1 Million
Q1 2021

May 13, 2021

BUY
$33.49 - $37.77 $20.7 Million - $23.4 Million
618,619 Added 118.05%
1,142,643 $41.4 Million
Q4 2020

Feb 16, 2021

SELL
$33.47 - $42.56 $17.9 Million - $22.8 Million
-535,564 Reduced 50.54%
524,024 $19.3 Million
Q3 2020

Nov 12, 2020

BUY
$31.75 - $37.25 $25.7 Million - $30.1 Million
809,168 Added 323.12%
1,059,588 $38.9 Million
Q2 2020

Aug 13, 2020

SELL
$30.12 - $36.54 $13.3 Million - $16.1 Million
-440,576 Reduced 63.76%
250,420 $8.19 Million
Q1 2020

May 13, 2020

BUY
$27.03 - $38.62 $2.45 Million - $3.51 Million
90,765 Added 15.12%
690,996 $21.4 Million
Q4 2019

Feb 12, 2020

SELL
$32.92 - $37.36 $40.9 Million - $46.4 Million
-1,240,952 Reduced 67.4%
600,231 $23.5 Million
Q3 2019

Nov 13, 2019

BUY
$32.49 - $42.13 $47.4 Million - $61.5 Million
1,460,000 Added 383.02%
1,841,183 $66.2 Million
Q2 2019

Aug 07, 2019

SELL
$36.98 - $41.52 $11.7 Million - $13.1 Million
-316,571 Reduced 45.37%
381,183 $16.5 Million
Q1 2019

May 08, 2019

BUY
$37.5 - $41.2 $2.71 Million - $2.98 Million
72,221 Added 11.55%
697,754 $29.6 Million
Q4 2018

Feb 12, 2019

BUY
$38.47 - $43.86 $2.56 Million - $2.92 Million
66,560 Added 11.91%
625,533 $27.3 Million
Q3 2018

Nov 13, 2018

SELL
$34.47 - $41.81 $16.2 Million - $19.6 Million
-469,125 Reduced 45.63%
558,973 $24.6 Million
Q2 2018

Aug 02, 2018

SELL
$32.98 - $35.16 $9.48 Million - $10.1 Million
-287,565 Reduced 21.86%
1,028,098 $37.3 Million
Q1 2018

May 14, 2018

BUY
$31.91 - $37.02 $8.63 Million - $10 Million
270,400 Added 25.87%
1,315,663 $46.7 Million
Q4 2017

Feb 09, 2018

SELL
$33.26 - $35.29 $4.14 Million - $4.39 Million
-124,462 Reduced 10.64%
1,045,263 $37.9 Million
Q3 2017

Nov 14, 2017

BUY
$31.0 - $34.15 $11 Million - $12.1 Million
354,050 Added 43.41%
1,169,725 $41.8 Million
Q2 2017

Aug 14, 2017

BUY
N/A
815,675
815,675 $27.4 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $150B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.